Quick Detail:
Product Name:Sorafenib tosylate
Other Name:Sorafinib mesylate;1-(4-Chloro-3-(trifluoroMethyl)phenyl)-3-(4-((2- (MethylcarbaMoyl)pyridin-4-yl)oxy)phenyl)urea Mono(4- Methylbenzenesulfonate);4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide monomethanesulfonate
CAS:475207-59-1
MF:C21H16ClF3N4O3.C7H8SO3
MW:637.03
Assay:99%min
Appearence:White crystalline powder
Drug category:Anticancer drug
Purpose:This product is mainly used for the treatment of liver and renal cell carcinoma of the clinical anti-cancer agents.
Package:1kg/bag
Function&Usage:
Sorafenib tosylate, also named nexavar, is a small-molecule anticancer compound. It is also a novel oral Raf kinase and a vascular endothelial receptor (VEGFR) inhibitor. It inhibits tumor cell proliferation and tumor angiogenesis [2]. To HepG2 cells (1× 106), the IC50 of sorafenib tosylate is 2.09μg/ml.
Raf is a mitogen-stimulated protein kinase that functions as a component of the signaling cascade that leads to the stimulation of mitogen-activated protein kinase.
Vascular endothelial (VEGF) is a highly specific mitogen for vascular endothelial cells.
Treatment with nexavar potently inhibited the cell proliferation of MV4-11 cells (FLT3-ITD) in a dose-dependent manner with an IC50 of 0.88 nM. In MV4-11 cells, sorafenib tosylate of a concentration of 100 nM induced 43.6±5.2% of the cells to undergo apoptosis whereas in EOL-1 cells a concentration as low as 10 nM induced 89.29±1.8% of the cells to be apoptotic.
Nude rats at the age of 6 weeks injected with 105 MDA-MB-231 cells were involved. After monotherapy with sorafenib tosylate a significant reduction of the osteolytic lesion volume was observed on days 45 and 55 and of the soft tissue component volume on day 55 in comparison to untreated animals (p < 0.05). Compared to controls, treatment with sorafenib tosylate made bone metastases show significantly decreased values of Amplitude A and kep from day 35 to 55 (Amplitude A: p<0.01; kep p<0.01 on days 35 and 55; p<0.05 on day 45)
COA:
Items of analysis |
Specification |
Results |
Description | off-white powder | Conforms |
Loss on drying | NMT 1.0% | 0.7% |
Water content | NMT 0.5% | 0.13% |
Single impurity | NMT0.1% | 0.07% |
Total impurity | NMT 0.5% | 0.29% |
Purity(HPLC) | NLT 99.0% | 99.71% |
Conclusion | Qualified |